Skip Nav Destination
Issues
1 July 2013
-
Cover Image
Cover Image
The cover shows a section from a human pancreatic ductal adenocarcinoma stained for cytokeratin 7 (green) and CCL2 (red) with a nuclear (Topro) counterstain (blue). Immunofluorescence confocal image (×63) reveals that the malignant ductal epithelium as well as cells within the tumor stroma produce CCL2. This chemokine plays a key role in the recruitment of inflammatory monocytes (CCR2+) from the bone marrow to both the primary tumor and premetastatic liver, where these cells promote growth and metastasis in pancreatic cancer. For details, see the article by Sanford and colleagues on page 3404 of this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Translations
CCR New Strategies
Molecular Pathways
Review
Human Cancer Biology
ETS2 Mediated Tumor Suppressive Function and MET Oncogene Inhibition in Human Non–Small Cell Lung Cancer
Mohamed Kabbout; Melinda M. Garcia; Junya Fujimoto; Diane D. Liu; Denise Woods; Chi-Wan Chow; Gabriela Mendoza; Amin A. Momin; Brian P. James; Luisa Solis; Carmen Behrens; J. Jack Lee; Ignacio I. Wistuba; Humam Kadara
High Prevalence of BRCA1 and BRCA2 Germline Mutations with Loss of Heterozygosity in a Series of Resected Pancreatic Adenocarcinoma and Other Neoplastic Lesions
Aimee L. Lucas; Reena Shakya; Marla D. Lipsyc; Elana B. Mitchel; Sheila Kumar; Caroline Hwang; Liyong Deng; Catherine Devoe; John A. Chabot; Matthias Szabolcs; Thomas Ludwig; Wendy K. Chung; Harold Frucht
Author Choice
Inflammatory Monocyte Mobilization Decreases Patient Survival in Pancreatic Cancer: A Role for Targeting the CCL2/CCR2 Axis
Dominic E. Sanford; Brian A. Belt; Roheena Z. Panni; Allese Mayer; Anjali D. Deshpande; Danielle Carpenter; Jonathan B. Mitchem; Stacey M. Plambeck-Suess; Lori A. Worley; Brian D. Goetz; Andrea Wang-Gillam; Timothy J. Eberlein; David G. Denardo; Simon Peter Goedegebuure; David C. Linehan
TIE-2 and VEGFR Kinase Activities Drive Immunosuppressive Function of TIE-2–Expressing Monocytes in Human Breast Tumors
Mark Ibberson; Sylvian Bron; Nicolas Guex; Eveline Faes-van't Hull; Assia Ifticene-Treboux; Luc Henry; Hans-Anton Lehr; Jean-François Delaloye; George Coukos; Ioannis Xenarios; Marie-Agnès Doucey
PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies
Benjamin J. Chen; Bjoern Chapuy; Jing Ouyang; Heather H. Sun; Margaretha G.M. Roemer; Mina L. Xu; Hongbo Yu; Christopher D.M. Fletcher; Gordon J. Freeman; Margaret A. Shipp; Scott J. Rodig
Author Choice
Nonequivalent Gene Expression and Copy Number Alterations in High-Grade Serous Ovarian Cancers with BRCA1 and BRCA2 Mutations
Joshy George; Kathryn Alsop; Dariush Etemadmoghadam; Heather Hondow; Thomas Mikeska; Alexander Dobrovic; Anna deFazio; for the Australian Ovarian Cancer Study Group; Gordon K. Smyth; Douglas A. Levine; Gillian Mitchell; David D. Bowtell
Cancer Therapy: Preclinical
Author Choice
Synergistic Effects of Metformin Treatment in Combination with Gefitinib, a Selective EGFR Tyrosine Kinase Inhibitor, in LKB1 Wild-type NSCLC Cell Lines
Floriana Morgillo; Ferdinando Carlo Sasso; Carminia Maria Della Corte; Donata Vitagliano; Elena D'Aiuto; Teresa Troiani; Erika Martinelli; Ferdinando De Vita; Michele Orditura; Raffaele De Palma; Fortunato Ciardiello
NMS-E973, a Novel Synthetic Inhibitor of Hsp90 with Activity against Multiple Models of Drug Resistance to Targeted Agents, Including Intracranial Metastases
Gianpaolo Fogliatto; Laura Gianellini; Maria G. Brasca; Elena Casale; Dario Ballinari; Marina Ciomei; Anna Degrassi; Anna De Ponti; Massimiliano Germani; Marco Guanci; Mauro Paolucci; Paolo Polucci; Micaela Russo; Francesco Sola; Barbara Valsasina; Carlo Visco; Fabio Zuccotto; Daniele Donati; Eduard Felder; Enrico Pesenti; Arturo Galvani; Sergio Mantegani; Antonella Isacchi
Disrupting Protein NEDDylation with MLN4924 Is a Novel Strategy to Target Cisplatin Resistance in Ovarian Cancer
Steffan T. Nawrocki; Kevin R. Kelly; Peter G. Smith; Claudia M. Espitia; Anthony Possemato; Sean A. Beausoleil; Michael Milhollen; Stephen Blakemore; Michael Thomas; Allison Berger; Jennifer S. Carew
Imaging, Diagnosis, Prognosis
Tumor Heterogeneity and Permeability as Measured on the CT Component of PET/CT Predict Survival in Patients with Non–Small Cell Lung Cancer
Thida Win; Kenneth A. Miles; Sam M. Janes; Balaji Ganeshan; Manu Shastry; Raymondo Endozo; Marie Meagher; Robert I. Shortman; Simon Wan; Irfan Kayani; Peter J. Ell; Ashley M. Groves
Cancer Therapy: Clinical
Clinical Activity and Safety of Combination Therapy with Temsirolimus and Bevacizumab for Advanced Melanoma: A Phase II Trial (CTEP 7190/Mel47)
Craig L. Slingluff, Jr; Gina R. Petroni; Kerrington R. Molhoek; David L. Brautigan; Kimberly A. Chianese-Bullock; Amber L. Shada; Mark E. Smolkin; Walter C. Olson; Alison Gaucher; Cheryl Murphy Chase; William W. Grosh; Geoffrey R. Weiss; Aubrey G. Wagenseller; Anthony J. Olszanski; Lainie Martin; Sofia M. Shea; Gulsun Erdag; Prahlad Ram; Jeffrey E. Gershenwald; Michael J. Weber
Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer
Ana M. Aparicio; Andrea L. Harzstark; Paul G. Corn; Sijin Wen; John C. Araujo; Shi-Ming Tu; Lance C. Pagliaro; Jeri Kim; Randall E. Millikan; Charles Ryan; Nizar M. Tannir; Amado J. Zurita; Paul Mathew; Wadih Arap; Patricia Troncoso; Peter F. Thall; Christopher J. Logothetis
Phase I Study of Pazopanib in Patients with Advanced Solid Tumors and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study
Stephen I. Shibata; Vincent Chung; Timothy W. Synold; Jeffrey A. Longmate; A. Benjamin Suttle; Lone H. Ottesen; Heinz-Josef Lenz; Shivaani Kummar; R. Donald Harvey; Anne L. Hamilton; Bert H. O'Neil; John Sarantopoulos; Patricia LoRusso; Michelle A. Rudek; Afshin Dowlati; Daniel L. Mulkerin; Chandra P. Belani; Leena Gandhi; S. Cecilia Lau; S. Percy Ivy; Edward M. Newman
Vaccination with Dendritic Cell/Tumor Fusions following Autologous Stem Cell Transplant Induces Immunologic and Clinical Responses in Multiple Myeloma Patients
Jacalyn Rosenblatt; Irit Avivi; Baldev Vasir; Lynne Uhl; Nikhil C. Munshi; Tami Katz; Bimalangshu R. Dey; Poorvi Somaiya; Heidi Mills; Federico Campigotto; Edie Weller; Robin Joyce; James D. Levine; Dimitrios Tzachanis; Paul Richardson; Jacob Laubach; Noopur Raje; Vassiliki Boussiotis; Yan Emily Yuan; Lina Bisharat; Viki Held; Jacob Rowe; Kenneth Anderson; Donald Kufe; David Avigan
A Multicenter, First-in-Pediatrics, Phase 1, Pharmacokinetic and Pharmacodynamic Study of Ridaforolimus in Patients with Refractory Solid Tumors
Lia Gore; Tanya M. Trippett; Howard M. Katzenstein; Jessica Boklan; Aru Narendran; Amy Smith; Margaret E. Macy; Katherine Rolla; for the Pediatric Oncology Experimental Therapeutics Investigators' Consortium (POETIC); Narayana Narashimhan; Rachel M. Squillace; Christopher D. Turner; Frank G. Haluska; Michael Nieder
A Phase I, Open-Label Study of Siltuximab, an Anti–IL-6 Monoclonal Antibody, in Patients with B-cell Non-Hodgkin Lymphoma, Multiple Myeloma, or Castleman Disease
Razelle Kurzrock; Peter M. Voorhees; Corey Casper; Richard R. Furman; Luis Fayad; Sagar Lonial; Hossein Borghaei; Sundar Jagannath; Lubomir Sokol; Saad Z. Usmani; Helgi van de Velde; Xiang Qin; Thomas A. Puchalski; Brett Hall; Manjula Reddy; Ming Qi; Frits van Rhee
First-in-Human Phase I Dose-Escalation Study of the HSP90 Inhibitor AUY922 in Patients with Advanced Solid Tumors
Cristiana Sessa; Geoffrey I. Shapiro; Kapil N. Bhalla; Carolyn Britten; Karen S. Jacks; Monica Mita; Vali Papadimitrakopoulou; Tim Pluard; Thomas A. Samuel; Mikhail Akimov; Cornelia Quadt; Cristina Fernandez-Ibarra; Hong Lu; Stuart Bailey; Sandra Chica; Udai Banerji
Predictive Biomarkers and Personalized Medicine
Author Choice
Identification and Analysis of In Vivo VEGF Downstream Markers Link VEGF Pathway Activity with Efficacy of Anti-VEGF Therapies
Matthew J. Brauer; Guanglei Zhuang; Maike Schmidt; Jenny Yao; Xiumin Wu; Joshua S. Kaminker; Stefanie S. Jurinka; Ganesh Kolumam; Alicia S. Chung; Adrian Jubb; Zora Modrusan; Tomoko Ozawa; C. David James; Heidi Phillips; Benjamin Haley; Rachel N.W. Tam; Anne C. Clermont; Jason H. Cheng; Sherry X. Yang; Sandra M. Swain; Daniel Chen; Stefan J. Scherer; Hartmut Koeppen; Ru-Fang Yeh; Peng Yue; Jean-Philippe Stephan; Priti Hegde; Napoleone Ferrara; Mallika Singh; Carlos Bais
Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer
Fabrice André; Thomas Bachelot; Mario Campone; Florence Dalenc; Jose M. Perez-Garcia; Sara A. Hurvitz; Nicholas Turner; Hope Rugo; John W. Smith; Stephanie Deudon; Michael Shi; Yong Zhang; Andrea Kay; Diana Graus Porta; Alejandro Yovine; José Baselga
Lactate Dehydrogenase B: A Metabolic Marker of Response to Neoadjuvant Chemotherapy in Breast Cancer
Jennifer B. Dennison; Jennifer R. Molina; Shreya Mitra; Ana M. González-Angulo; Justin M. Balko; María G. Kuba; Melinda E. Sanders; Joseph A. Pinto; Henry L. Gómez; Carlos L. Arteaga; Robert E. Brown; Gordon B. Mills
Corrections
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.